Astra stakes a claim for early camizestrant
But this adds another complexity, and has camizestrant really scored a first-line win?
Regeneron’s Met bet falls short
The Met x Met ADC REGN5093-M114 has been discontinued, but a Met x Met bispecific antibody remains.
ASCO-GU – another strike against Cabometyx
A triplet did worse than control in first-line kidney cancer.
ASCO-GU – Arcus goes it alone in HIF2α
Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.
What future for Lag3 blockade?
Opdualag chalks up another failure, this time in the extension of an approved use.
ASCO-GU – Corbus backs Chinese data with its own
But investors remain unimpressed with the Nectin-4 ADC Corbus bought for just $7.5m.
ASCO-GU – some backing for Pfizer's EZH2 plan
Phase 1 data give investors a benchmark for mevrometostat's pivotal Mevpro-1 trial.
ASCO-GU – Pfizer eyes broader Talzenna use
But the overall survival benefit in prostate cancer is still driven by HRR mutations.
ASCO-GU – Pfizer looks for bigger bladder cancer invasion
Padcev still looks good in first-line bladder, but Pfizer hopes to make a mark in muscle-invasive disease.
Orca heads to the FDA
Orca-T is said to hit in a pivotal trial, but the comparator regimen could be debated.
